These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
289 related articles for article (PubMed ID: 2778483)
21. Randomized comparison of 36-hour intermediate-dose versus 4-hour high-dose methotrexate infusions for remission induction in relapsed childhood acute lymphoblastic leukemia. Wolfrom C; Hartmann R; Fengler R; Brühmüller S; Ingwersen A; Henze G J Clin Oncol; 1993 May; 11(5):827-33. PubMed ID: 8487046 [TBL] [Abstract][Full Text] [Related]
22. Oral methotrexate/6-mercaptopurine may be superior to a multidrug LSA2L2 Maintenance therapy for higher risk childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study. Schmiegelow K; Heyman M; Kristinsson J; Mogensen UB; Rosthøj S; Vettenranta K; Wesenberg F; Saarinen-Pihkala U; J Pediatr Hematol Oncol; 2009 Jun; 31(6):385-92. PubMed ID: 19648786 [TBL] [Abstract][Full Text] [Related]
23. Unexpected acute neurologic toxicity in the treatment of children with acute lymphoblastic leukemia. Winick NJ; Bowman WP; Kamen BA; Roach ES; Rollins N; Jacaruso D; Buchanan GR J Natl Cancer Inst; 1992 Feb; 84(4):252-6. PubMed ID: 1734087 [TBL] [Abstract][Full Text] [Related]
24. [Treatment of childhood acute lymphoblastic leukemia: randomized trials of protocols CCLSG-L 841 and I 841. (Phase III study). Children's Cancer and Leukemia Study Group]. Rinsho Ketsueki; 1989 Jul; 30(7):967-74. PubMed ID: 2681882 [TBL] [Abstract][Full Text] [Related]
25. High survival rate in advanced-stage B-cell lymphomas and leukemias without CNS involvement with a short intensive polychemotherapy: results from the French Pediatric Oncology Society of a randomized trial of 216 children. Patte C; Philip T; Rodary C; Zucker JM; Behrendt H; Gentet JC; Lamagnère JP; Otten J; Dufillot D; Pein F J Clin Oncol; 1991 Jan; 9(1):123-32. PubMed ID: 1985161 [TBL] [Abstract][Full Text] [Related]
26. Benefits of the intermittent use of 6-mercaptopurine and methotrexate in maintenance treatment for low-risk acute lymphoblastic leukemia in children: randomized trial from the Brazilian Childhood Cooperative Group--protocol ALL-99. Brandalise SR; Pinheiro VR; Aguiar SS; Matsuda EI; Otubo R; Yunes JA; Pereira WV; Carvalho EG; Cristofani LM; Souza MS; Lee ML; Dobbin JA; Pombo-de-Oliveira MS; Lopes LF; Melnikoff KN; Brunetto AL; Tone LG; Scrideli CA; Morais VL; Viana MB J Clin Oncol; 2010 Apr; 28(11):1911-8. PubMed ID: 20212252 [TBL] [Abstract][Full Text] [Related]
27. Intermediate-dose methotrexate and intravenous 6-mercaptopurine chemotherapy for children with acute lymphoblastic leukemia who did not respond to initial induction therapy. Ogden AK; Pollock BH; Bernstein ML; Camitta B; Buchanan GR J Pediatr Hematol Oncol; 2002; 24(3):182-7. PubMed ID: 11990303 [TBL] [Abstract][Full Text] [Related]
28. Risk of relapse in childhood acute lymphoblastic leukemia is related to RBC methotrexate and mercaptopurine metabolites during maintenance chemotherapy. Nordic Society for Pediatric Hematology and Oncology. Schmiegelow K; Schrøder H; Gustafsson G; Kristinsson J; Glomstein A; Salmi T; Wranne L J Clin Oncol; 1995 Feb; 13(2):345-51. PubMed ID: 7531219 [TBL] [Abstract][Full Text] [Related]
29. Extended triple intrathecal chemotherapy trial for prevention of CNS relapse in good-risk and poor-risk patients with B-progenitor acute lymphoblastic leukemia: a Pediatric Oncology Group study. Pullen J; Boyett J; Shuster J; Crist W; Land V; Frankel L; Iyer R; Backstrom L; van Eys J; Harris M J Clin Oncol; 1993 May; 11(5):839-49. PubMed ID: 8487048 [TBL] [Abstract][Full Text] [Related]
30. Pulses of vincristine and dexamethasone in addition to intensive chemotherapy for children with intermediate-risk acute lymphoblastic leukaemia: a multicentre randomised trial. Conter V; Valsecchi MG; Silvestri D; Campbell M; Dibar E; Magyarosy E; Gadner H; Stary J; Benoit Y; Zimmermann M; Reiter A; Riehm H; Masera G; Schrappe M Lancet; 2007 Jan; 369(9556):123-31. PubMed ID: 17223475 [TBL] [Abstract][Full Text] [Related]
31. Current results of studies of immunophenotype-, age- and leukocyte-based therapy for children with acute lymphoblastic leukemia. The Pediatric Oncology Group. Crist W; Shuster J; Look T; Borowitz M; Behm F; Bowman P; Frankel L; Pullen J; Krance R; Steuber P Leukemia; 1992; 6 Suppl 2():162-6. PubMed ID: 1578922 [TBL] [Abstract][Full Text] [Related]
32. Toxic epidermal necrolysis following combination of methotrexate and trimethoprim-sulfamethoxazole. Yang CH; Yang LJ; Jaing TH; Chan HL Int J Dermatol; 2000 Aug; 39(8):621-3. PubMed ID: 10971734 [TBL] [Abstract][Full Text] [Related]
33. Treatment of occult or late overt testicular relapse in children with acute lymphoblastic leukemia: a Pediatric Oncology Group study. Wofford MM; Smith SD; Shuster JJ; Johnson W; Buchanan GR; Wharam MD; Ritchey AK; Rosen D; Haggard ME; Golembe BL J Clin Oncol; 1992 Apr; 10(4):624-30. PubMed ID: 1548525 [TBL] [Abstract][Full Text] [Related]
34. Response of children with high-risk acute lymphoblastic leukemia treated with and without cranial irradiation: a report from the Children's Cancer Group. Nachman J; Sather HN; Cherlow JM; Sensel MG; Gaynon PS; Lukens JN; Wolff L; Trigg ME J Clin Oncol; 1998 Mar; 16(3):920-30. PubMed ID: 9508174 [TBL] [Abstract][Full Text] [Related]
35. Relation between the duration of remission and hyperglycemia during induction chemotherapy for acute lymphocytic leukemia with a hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone/methotrexate-cytarabine regimen. Weiser MA; Cabanillas ME; Konopleva M; Thomas DA; Pierce SA; Escalante CP; Kantarjian HM; O'Brien SM Cancer; 2004 Mar; 100(6):1179-85. PubMed ID: 15022284 [TBL] [Abstract][Full Text] [Related]
36. [Results and experiences with a modified BFM protocol for treatment of recurrences in children with acute lymphoblastic leukemia in East German areas]. Sauerbrey A; Zintl F; Malke H; Reimann M; Maaser M; Domula M; Dörffel W; Eggers G; Exadaktylos P; Kotte W Klin Padiatr; 1993; 205(4):281-7. PubMed ID: 8377448 [TBL] [Abstract][Full Text] [Related]
37. [Clinical trial of protocol-AL851 for children with high-risk acute lymphoblastic leukemia. Kyushu Yamaguchi Children's Cancer Study Group (KYCCSG)]. Matsuzaki A; Ishii E; Ueda K; Yanai F; Nibu K; Take H; Koga H; Miyazaki S; Inoue T; Miyake K Rinsho Ketsueki; 1994 Sep; 35(9):862-70. PubMed ID: 7967055 [TBL] [Abstract][Full Text] [Related]
38. A comparison of two regimens for high-risk acute lymphocytic leukemia in childhood. A Pediatric Oncology Group Study. van Eys J; Berry D; Crist W; Doering E; Fernbach D; Pullen J; Shuster J; Wharam M Cancer; 1989 Jan; 63(1):23-9. PubMed ID: 2910421 [TBL] [Abstract][Full Text] [Related]
39. Systemic exposure to mercaptopurine as a prognostic factor in acute lymphocytic leukemia in children. Koren G; Ferrazini G; Sulh H; Langevin AM; Kapelushnik J; Klein J; Giesbrecht E; Soldin S; Greenberg M N Engl J Med; 1990 Jul; 323(1):17-21. PubMed ID: 2355954 [TBL] [Abstract][Full Text] [Related]
40. Intensification of mercaptopurine/methotrexate maintenance chemotherapy may increase the risk of relapse for some children with acute lymphoblastic leukemia. Schmiegelow K; Björk O; Glomstein A; Gustafsson G; Keiding N; Kristinsson J; Mäkipernaa A; Rosthøj S; Szumlanski C; Sørensen TM; Weinshilboum R J Clin Oncol; 2003 Apr; 21(7):1332-9. PubMed ID: 12663723 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]